{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:10Z","timestamp":1786994410016,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"MS"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.msard.2020.102195","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T09:19:39Z","timestamp":1589361579000},"page":"102195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"special_numbering":"C","title":["B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran"],"prefix":"10.1016","volume":"43","author":[{"given":"Farinaz","family":"Safavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Nourbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2020.102195_bib0001","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.msard.2020.102195_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102165","article-title":"Natalizumab treatment: a case report in a patient with extended interval dosing approach","author":"Borriello","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"10.1016\/j.msard.2020.102195_bib0003","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.msard.2020.102195_bib0004","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"issue":"10223","key":"10.1016\/j.msard.2020.102195_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102195_bib0006","first-page":"1","article-title":"Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study","author":"Lechien","year":"2020","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"2","key":"10.1016\/j.msard.2020.102195_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"7","author":"Luna","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.102195_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577230","article-title":"Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS","author":"Najjar","year":"2020","journal-title":"J Neuroimmunol."},{"issue":"5","key":"10.1016\/j.msard.2020.102195_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7224\/1537-2073.2014-035","article-title":"Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans","volume":"17","author":"Nelson","year":"2015","journal-title":"Int J MS Care"},{"key":"10.1016\/j.msard.2020.102195_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6130","article-title":"Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China","author":"Pan","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.msard.2020.102195_bib0011","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.msard.2020.102195_bib0012","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.msard.2020.102195_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"10.1016\/j.msard.2020.102195_bib0014","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.msard.2020.102195_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol."},{"key":"10.1016\/j.msard.2020.102195_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","author":"Sormani","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102195_bib0017","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.msard.2020.102195_bib0018","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.msard.2020.102195_bib0019","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2020.102195_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"Williamson","year":"2015","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.msard.2020.102195_bib0021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102195_bib0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cell.2020.03.035","article-title":"A Genomic Perspective on the Origin and Emergence of SARS-CoV-2","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820302716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:27Z","timestamp":1761900747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820302716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":22,"alternative-id":["S2211034820302716"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102195","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102195"}}